谷氨酰胺颗粒对重度慢性乙型病毒性肝炎患者肠道通透性、内毒素血症与肝功能的影响

表1 对照组与治疗组治疗前后肝功能、ET、L/M比较 (n = 30, mean±SD)

	ALT(U)	AST(U)	TBIL(Umol/L)	PT(s)	CHE(U)	ALB(g/L)	ET(EU/mL)	L/M
对照组
治疗前	420.38±271.36	306.19±220.58	267.53±156.75	15.99±3.15	4166.24±1365.18	34.81±5.96	0.21±0.05	0.0425±0.0183
治疗后	220.74±177.55b	74.81±34.86b	163.39±136.85b	14.49±2.70a	5058.47±1569.59b	37.74±6.06a	0.155±0.04b	0.0335±0.012a
治疗组
治疗前	418.55±192.89	361.99±188.68	255.73±129.53	15.29±2.27	3871.96±1001.37	36.93±10.57	0.209±0.054	0.04013±0.0154
治疗后	136.69±60.01b	80.35±40.57b	87.08±37.67b	13.36±1.93b	5173.00±1177.16b	37.88±4.88	0.115±0.051b	0.0203±0.0108b

对照组: t = 8.604, 6.162, 2.781, 2.366, 5.673, 2.245, 5.304, 2.216;

^aP<0.05,

^bP<0.01 vs 治疗前; 治疗组: t = 10.338, 8.330, 9.053, 5.833, 10.752, 0.494, 7.747, 8.530; ^bP<0.01 vs 治疗前.

表2 对照组与治疗组治疗前后肝功能、ET、L/M差值变化 (n = 30, mean±SD)

	ALT(U)	TBIL(Umol/L)	CHE(U)	ET(EU/mL)	L/M
对照组	199.65±127.09	94.13±172.67	-892.23±861.41	0.055±0.057	0.0089±0.0228
治疗组	281.86±149.34a	168.65±102.04b	-1301.04±662.78c	0.093±0.066d	0.0198±0.0128e

t = 2.296,

^aP = 0.025; t = 2.035,

^bP = 0.046; t = 2.010,

^cP = 0.044; t = 2.412,

^dP<0.019; t = 2.300,

^eP = 0.025.